Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?

Leukemia and Lymphoma

Volumn 32, Issue 3-4, 1999, Pages 223-236

  Schultze, Joachim L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anergy; CD40; Lymphoma; T lymphocyte; Tolerance

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; B CELL LYMPHOMA; B LYMPHOCYTE; CELLULAR IMMUNITY; CLONAL ANERGY; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0033055174     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909167383     Document Type: Review

References (99)

1. Eisen, H.N., N. Sakato, and S.J. Hall, 1975. Myeloma proteins as tumor-specific antigens. Transplant. Proc. 7:209-214.
2. Janeway, C.A., Jr., N. Sakato, and H.N. Eisen. 1975. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc. Natl. Acad. Sci. USA 72:2357-2360.
3. Smith, M.E., C.S. Holgate, J.M. Williamson, I. Grigor, P. Quirke, and C.C. Bird. 1987. Major histocompatibility complex class II antigen expression in B and T cell non-Hodgkin's lymphoma. J. Clin. Pathol. 40:34-41.
4. Moller, P., B. Herrmann, G. Moldenhauer, and F. Momburg. 1987. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Inn. J. Cancer 40:32-39.
5. Freedman, A.S., and L.M. Nadler. 1991. Immunologic markers in non-Hodgkin's lymphoma. Hematol. Oncol. Clin. North. Am. 5:871-889.
6. Schultze, J.L., A.A. Cardoso, G.J. Freeman, M.J. Seamon, J. Daley, G.S. Pinkus, J.G. Gribben, and L.M. Nadler. 1995. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 92:8200-8204.
7. Longo, D.L. 1997. Lymphoma. Curr. Opin. Oncol. 9:389-391.
8. Bogen, B., B. Malissen, and W. Haas. 1986. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 16:1373-1378.
9. Campbell, M.J., W. Carroll, S. Kon, K. Thielemans, J.B. Rothbard, and S.L. Levy, R. 1987. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139:2825-2833.
10. Lauritzsen, G.F., S. Weiss, Z. Dembic, and B. Bogen. 1994. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. USA 91:5700-5704.
11. Levitsky, H.I., J. Montgomery, M. Ahmadzadeh, K. Staveley-O'Carroll, F. Guarnieri, D.L. Longo, and L.W. Kwak. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156:3858-3865.
12. Kwak, L.W., H.A. Young, R.W. Pennington, and S.D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93:10972-10977.
13. Kwak, L.W., M.J. Campbell, D.K. Czerwinski, S. Hart, R.A. Miller, and R. Levy. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209-1215.
14. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
15. Nelson, E.L., X. Li, F.J. Hsu, L.W. Kwak, R. Levy, C. Clayberger, and A.M. Krensky. 1996. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88:580-589.
16. Chen, L. 1998. Immunological ignorance of silent antigens as an explanation of tumor evasion, Immunol. Today 19:27-30.
17. Miller, J.F., and W.R. Heath. 1993. Self-ignorance in the peripheral T-cell pool, Immunol. Rev. 133:131-150.
18. Guinan, B.C., J.G. Gribben, V.A. Boussiotis, G.J. Freeman, and L.M. Nadler. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-3282.
19. Schultze, J.L., L.M. Nadler, and J.G. Gribben. 1996. B7-mediated costimulation and the immune response. Blood. Rev. 10:111-127.
20. Levitsky, H.I. 1996. Tumors derived from antigen presenting cells. Semin. Immunol. 8:281-287.
21. Sotomayor, E.M., I. Borrello, and H.I. Levitsky. 1996. Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog. 7:433-456.
22. Bogen, B. 1996. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26:2671-2679.
23. Bogen, B., Z. Dembic, and S. Weiss. 1993. Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO 12:357-363.
24. Vyth-Dreese, F.A., T.A. Dellemijn, J.W. van Oostveen, C.A. Feltkamp, and A. Hekman. 1995. Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood 85:2802-2812.
25. Shamash, J., D.C. Davies, A. Salam, A.Z. Rohatiner, B.D. Young, and T.A. Lister. 1995. Induction of CD80 expression in low-grade B cell lymphoma - a potential immunotherapeutic target. Leukemia 9:1349-1352.
26. Dorfman, D.M., J.L. Schultze, A. Shahsafaei, S. Michalak, J.G. Gribben, G.J. Freeman, G.S. Pinkus, and L.M. Nadler. 1997. In Vivo Expression of B7-1 and B7-2 on Follicular Lymphoma is Not Sufficient to Induce Significant T Cell Proferation But is Sufficient to Prevent T Cell Anergy In Vitro. Blood 90:4297-4306.
27. Blay, J.Y., N. Burdin, F. Rousset, G. Lenoir, P. Biron, T. Philip, J. Banchereau, and M.C. Favrot. 1993. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82:2169-2174.
28. Kopper, L., A. Ladanyi, R. Mihalik, and P. Nagy. 1994. Loss of transforming growth factor beta I regulatory activity in human non Hodgkin lymphomas. Antican. Res. 14:119-122.
29. Bost, K.L., S.C. Bieligk, and B.M. Jaffe. 1995. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J. Immunol. 154:718-729.
30. Schultze, J.L., S. Michalak, M.J. Seamon, J.G. Gribben, and L.M. Nadler. 1996. CD40 Activated Follicular Lymphoma Cells Are Resistant to And Can Overcome Generalized T Cell Unresponsiveness Induced by IL-10 and TGFβ1. Blood 88(Suppl)
31. Zinkernagel, R.M. 1996. Immunology taught by viruses. Science 271:173-178.
32. Nikolic, B., and M. Sykes. 1997. Bone marrow chimerism and transplantation tolerance. Curr. Opin. Immunol. 9:634-640.
33. Ohashi, P.S., S. Oehen, K. Buerki, H. Pircher, CT. Ohashi, B. Odermatt, B. Malissen, R.M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305-317.
34. von Herrath, M., and A. Holz. 1997. Pathological changes in the islet milieu precede infiltration of islets and destruction of beta-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM, J. Autoimmun. 10:231-238.
35. Von Herrath, M.G., S. Guerder, H. Lewicki, R.A. Flavell, and M.B. Oldstone. 1995. Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 3:727-738.
36. Von Herrath, M.G., and M.B. Oldstone. 1997. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185:531-539.
37. Schwartz, R.H. 1990. A Cell Culture Model for T Lymphocyte Clonal Anergy. Science 248:1349-1356.
38. Gimmi, C.D., Freeman, G.J., Gribben, J.G., Sugita, K., Freedman, A.S., Morimoto, C., Nadler, L.M. 1991. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete intesleukin 2. Proc. Natl. Acad. Sci. USA 88:6575-6579.
39. Gimmi, C.D., G.J. Freeman, J.G. Gribben, G. Gray, and L.M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90:6586-6590.
40. Schwartz, R.H. 1993. T Cell Anergy. Scientific American, 62-71.
41. Schwartz, R.H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 9:351-357.
42. Sprent, J., and S.R. Webb. 1995. Intrathymic and extrathymic clonal deletion of T cells. Curr. Opin. Immunol. 7:196-205.
43. Goodnow, C.C. 1996. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. USA 93:2264-2271.
44. Waldmann, H., and S. Cobbold. 1993. The use of monoclonal antibodies to achieve immunological tolerance. Immunol. Today 14:247-251.
45. Cobbold, S.P., E. Adams, S.E. Marshall, J.D. Davies, and H. Waldmann. 1996. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol. Rev. 149:5-33.
46. Weiner, H.L., A. Friedman, A. Miller, S.J. Khoury, A. al-Sabbagh, L. Santos, M. Sayegh, R.B. Nussenblatt, D.E. Trentham, and D.A. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:809-837.
47. Strober, W., B. Kelsall, I. Fuss, T. Marth, B. Ludviksson, R. Ehrhardt, and M. Neurath. 1997. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation, Immunol. Today 18:61-64.
48. Wojtowicz-Praga, S. 1997. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:165-177.
49. Groux, H., M. Bigler, J.E. de Vries, and M.G. Roncarolo. 1996. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184:19-29.
50. Buer, J., A. Lanoue, A. Franzke, C. Garcia, H. von Boehmer, and A. Sarukhan. 1998. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med. 187:177-183.
51. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741-746.
52. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, Hellstroml, and K.E. Hellstrom. 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523-532.
53. Johnston, J.V, A.R. Malacko, M.T. Mizuno, P. McGowan, I. Hellstrom, K.E. Hellstrom, H. Marquardt, and L. Chen. 1996. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. 183:791-800.
54. Wick, M., P. Dubey, H. Koeppen, CT. Siegel, P.E. Fields, L. Chen, J.A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
55. Huang, A.Y., A.T. Bruce, D.M. Pardoll, and H.I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769-776.
56. MacLennan, I.C., A. Gulbranson-Judge, K.M. Toellner, M. Casamayor-Palleja, E. Chan, D.M. Sze, S.A. Luther, and H.A. Orbea. 1997. The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol. Rev. 156:53-66.
57. Goodnow, C.C. 1997. Chance encounters and organized rendezvous. Immunol. Rev. 156:5-10.
58. Shokat, K.M., and C.C. Goodnow. 1995. Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 375:334-338.
59. Rathmell, J.C., M.P. Cooke, W.Y. Ho, J. Grein, S.E. Townsend, M.M. Davis, and C.C. Goodnow. 1995. CD95 (Fast-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376:181-184.
60. Cyster, J.G., and C.C. Goodnow. 1995. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 3:691-701.
61. Rathmell, J.C., S.E. Townsend, J.C. Xu, R.A. Flavell, and C.C. Goodnow. 1996. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87:319-329.
62. Staveley, O.C.K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178-1183.
63. Finke, J.H., A.H. Zea, J. Stanley, D.L. Longo, H. Mizoguchi, R.R. Tubbs, R.H. Wiltrout, J.J. O'Shea, S. Kudoh, and E. Klein. 1993. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53:5613-5616.
64. Massaia, M., C. Attisano, E. Beggiato, A. Bianchi, and A. Pileri. 1994. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br. J. Haematol. 88:886-888.
65. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing zeta chains in tumor-imfiltrating T-cells and NK cells of patients with coloractal carcinoma. Cancer Res. 53:5610-5612.
66. Schultze, J.L., V.A. Boussiotis, D. Dorfman, A.A. Cardoso, M.J. Seamen, H.M. Afonso, J.G. Gribben, and L.M. Nadler. 1995. Absence of Anti-Follicular Lymphoma (FL) Specific T Cell Mediated Immunity is Associated With Significant Reduction of T Cell Receptor Zeta Chain And Granzyme B Expression. Blood 86 (Suppl) 1073.
67. Wang, Q., J. Stanley, S. Kudoh, J. Myles, V. Kolenko, T. Yi, R.B. Tubbs, R, and J. Finke. 1995. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 155:1382-1392.
68. Guarini, A., L. Riera, A. Cignetti, L. Montacchini, M. Massaia, and R. Foa. 1997. Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood 89:212-218.
69. Mizoguchi, H., J.J. O'Shea, D.L. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798.
70. Salvadori, S., B. Gansbacher, A.M. Pizzimenti, and K.S. Zier. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. J. Immunol. 153:5176-5182.
71. Salvadori, S., and K. Zier. 1996. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J. Immunol. 156:2927-2932.
72. Zier, K., B. Gansbacher, and S. Salvadori. 1996. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Immunol. Today 17:39-45.
73. Moore, K.W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T.R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190.
74. Tada, T., S. Ohzeki, K. Utsumi, H. Takiuchi, M. Muramatsu, X.F. Li, ShimizuJ, H. Fujiwara, and T. Hamaoka. 1991. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immunol. 146:1077-1082.
75. De Waal Malefyt, R., H. Yssel, and J.E. de Vries. 1993. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 150:4754-4765.
76. Becker, J.C., C. Czerny, and E.B. Brocker. 1994. Maintenance of clonal anergy by endogenously produced IL-10. Inn. Immunol. 6:1605-1612.
77. Holter, W., F.S. Kalthoff, W.F. Pickl, C. Ebner, O. Majdic, D. Kraft, and Knapp W. 1994. Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells. Int. Immunol. 6:469-475.
78. Kurt, R.A., J.A. Park, M.C. Panelli, S.F. Schluter, J.J. Marchalonis, B. Carolus, and E.T. Akporiaye. 1995. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. J. Immunol. 154:3969-3974.
79. De Waal Malefyt, R., J. Haanen, H. Spits, M.G. Roncarolo, A.F. te Velde, C, K. Johnson, R. Kastelein, H. Yssel, and J.E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:915-924.
80. Grabbe, S., S. Bruvers, and R.D. Granstein. 1992. Effects of immunomodulatory cytokines on the presentation of tumor-associated antigens by epidermal Langerhans cells. J. Invest. Dermatol. 99:66S-68S.
81. Oswald, I.P., R.T. Gazzinelli, A. Sher, and S.L. James. 1992. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J. Immunol. 148:3578-3582.
82. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann. N.Y. Acad. Sci. 685:713-739.
83. Ding, L., P.S. Linsley, L.Y. Huang, R.N. Germain, and E.M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J. Immunol. 151:1224-1234.
84. Maeda, H., H. Kuwahara, Y. Ichimura, M. Ohtsuki, S. Kurakata, and A. Shiraishi. 1995. TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 155:4926-4932.
85. Skeen, M.J., M.A. Miller, T.M. Shinnick, and H.K. Ziegler. 1996. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156:1196-1206.
86. Schultze, J.L., M.J. Seamon, S. Michalak, J.G. Gribben, and L.M. Nadler. 1997. Autologous Tumor Infiltrating T Cells Cytotoxic For Follicular Lymphoma Cells Can Be Expanded In Vitro. Blood 89:3806-3816.
87. Lassila, O., O. Vainio, and P. Matzinger. 1988. Can B cells turn on virgin T cells? Nature 334:253-255.
88. Ho, W.Y., M.P. Cooke, C.C. Goodnow, and M.M. Davis. 1994. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4+ T cells. J. Exp. Med. 179:1539-1549.
89. Rammensee, H.G. 1991. Maintenance of self tolerance in CD4+ T lymphocytes by antigen presentation on resting B cells - a hypothesis. Bone Marrow Transplant 7 Suppl 1:26-28.
90. Eynon, E.E., and D.C. Parker. 1992. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 175:131-138.
91. Gilbert, K.M., and W.O. Weigle. 1994. Tolerogenicity of Resting and Activated B Cells. J. Exp. Med. 179:249-258.
92. Croft, M., L.M. Bradley, and S.L. Swain. 1994. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 152:2675-2685.
93. Dubey, C., and M. Croft. 1996. Accessory molecule regulation of naive CD4 T cell activation, Immunol. Res. 15:114-125.
94. Schultze, J.L., S. Michalak, J. Lowne, A. Wong, M.H. Gilleece, J.G. Gribben, and L.M. Nadler. submitted. Human Non-germinal center B cell IL-12 production is primarily regulated by T cell signals CD40L, IFN- and IL-10: Role of B cells in the maintenance of T cell responses.
95. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605-610.
96. Stevenson, F.K., D. Zhu, C.A. King, L.J. Ashworth, S. Kumar, and R.E. Hawkins. 1995. Idiotype DNA Vaccines Against B-cell Lymphoma. Immunol. Rev. 145:211-228.
97. Syrengelas, A.D., T.T. Chen, and R. Levy. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2:1038-1041.
98. Luna-Fineman, S., J.E. Lee, P.K. Wesley, C. Clayberger, and A.M. Krensky. 1992. Human Cytotoxic T-Lymphocytes Specific for Autologous Follicular Lymphoma Recognize Immunoglobulin in a Major Histocompatibility Complex Restricted Fashion. Cancer 70:2181-2186.
99. Wen, Y.J., and S.H. Lim. 1997. T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur. J. Immunol. 27:1043-1047.